You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

sustained deep molecular response

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Hepatocellular Carcinoma Trial in Singapore (Surgical Resection, Adjuvant Atezolizumab-Bevacizumab Therapy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Surgical Resection
  • Adjuvant Atezolizumab-Bevacizumab Therapy
  • Singapore, Singapore
  • +5 more
Aug 23, 2022

Liver Cirrhosis, Hepatitis C, Chronic, Epigenetic Disorder Trial in Guadalajara, Mexico City (Prolonged-Release Pirfenidone)

Recruiting
  • Liver Cirrhosis
  • +2 more
  • Prolonged-Release Pirfenidone
  • Guadalajara, Jalisco, Mexico
  • +1 more
Sep 13, 2022

Autonomic Dysfunction in Familial Mediterranean Fever

Recruiting
  • Familial Mediterranean Fever
  • Autonomic Dysfunction
  • Composite Autonomic Symptom Score-31
  • +12 more
  • Istanbul, Turkey
    Marmara University School of Medicine, Pendik Education and Rese
Oct 24, 2022

Chronic Myeloid Leukemia Trial in Germany (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Mannheim, Baden-Wuerttemberg, Germany
  • +69 more
Mar 21, 2022

Chronic Myeloid Leukemia Trial in Worldwide (Bosutinib, Ropeginterferon)

Recruiting
  • Chronic Myeloid Leukemia
  • Aalborg, Denmark
  • +17 more
Apr 4, 2022

Leukemia, Chronic Myeloid Trial in Campinas (Pioglitazone, imatinib discontinuation)

Active, not recruiting
  • Leukemia, Chronic Myeloid
  • Campinas, SP, Brazil
    Centro de Hematologia e Hemoterapia - Universidade Estadual de C
Nov 2, 2020

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in Moscow

Active, not recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Moscow, Russian Federation
    National Research Center for Hematology
Oct 1, 2020

Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed
  • Chronic Myeloid Leukemia
  • 3L Therapy
  • T315I
  • Lyon, France
    Novartis Investigative Site
Nov 9, 2022

Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Augusta, Georgia
  • +1 more
Jul 14, 2022

CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

Recruiting
  • CML
  • +3 more
  • Asciminib add-on
  • +3 more
  • Augusta, Georgia
  • +46 more
Jan 23, 2023

Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Tumors Trial in Melbourne

Not yet recruiting
  • Cutaneous Squamous Cell Carcinoma
  • +3 more
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
May 17, 2023

Leukemia, Chronic Myeloid Trial in Malaysia (Peginterferon-a-2a)

Active, not recruiting
  • Leukemia, Chronic Myeloid
  • Johor Bahru, Johor, Malaysia
  • +8 more
Sep 11, 2020

Chronyc Myeloid Leukemia Trial in Italy, Netherlands (Imatinib, Nilotinib)

Active, not recruiting
  • Chronyc Myeloid Leukemia
  • Alessandria, Italy
  • +81 more
Jan 4, 2022

Chronic Myeloid Leukemia Trial in Jena (Venetoclax)

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Jena, Germany
    Universitätsklinikum Jena
Jan 17, 2023

Action of Interferon in Treatment of Myeloproliferative

Recruiting
  • Myeloproliferative Neoplasm
    • Villejuif, Ile De France, France
      Inserm U1287
    Apr 28, 2023

    Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug Trial in Czechia (Imatinib withdrawal, Dasatinib, Nilotinib)

    Recruiting
    • Chronic Myeloid Leukemia, Chronic Phase
    • Withdrawal;Drug
    • Imatinib withdrawal
    • +2 more
    • Brno, Czechia
    • +7 more
    Aug 24, 2022

    Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

    Not yet recruiting
    • Chronic Myeloid Leukemia
    • Treatment-free Remission
    • TFR(Treatment-Free Remission)
    • (no location specified)
    Jun 27, 2022

    T-Cell and NK-Cell Tumor Trial

    Not yet recruiting
    • T-Cell and NK-Cell Neoplasm
      • (no location specified)
      Sep 28, 2023

      Observational Study to Assess Neuropathy in Diabetic Children

      Not yet recruiting
      • Diabetes Mellitus
      • uroflowmetry
      • +2 more
      • Budapest, Hungary
        Heim Pal National Pediatric Institute
      Aug 3, 2022

      Deep Neck Flexors Training, Post Isometric Relaxation Trial (pressure biofeedback, therapeutic ultra sound, infra red radiation)

      Not yet recruiting
      • Deep Neck Flexors Training
      • Post Isometric Relaxation
      • pressure biofeedback
      • +3 more
      • (no location specified)
      Oct 30, 2023

      The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer

      Not yet recruiting
      • Lung Cancer
        • (no location specified)
        Sep 13, 2022

        Glioma, Childhood Brainstem, Neuroblastoma Trial in San Francisco, Boston (External beam radiotherapy,

        Not yet recruiting
        • Glioma, Childhood Brainstem
        • Neuroblastoma
        • External beam radiotherapy
        • 131I-Metaiodobenzylguanidine (MIBG)
        • San Francisco, California
        • +1 more
        Aug 17, 2023

        Treatment Resistant Depression Trial in Queens (Medtronic SenSight Directional DBS lead)

        Recruiting
        • Treatment Resistant Depression
        • Medtronic SenSight Directional DBS lead
        • Queens, New York
          Zucker Hillside Hospital
        Oct 19, 2023

        Metastatic Melanoma Trial in Netherlands (drug, device, procedure)

        Terminated
        • Metastatic Melanoma
        • Vemurafenib plus cobimetinib
        • +3 more
        • Amsterdam, Netherlands
        • +9 more
        Nov 24, 2022